<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367196</url>
  </required_header>
  <id_info>
    <org_study_id>CC-90002-ST-001</org_study_id>
    <secondary_id>2015-000101-39</secondary_id>
    <nct_id>NCT02367196</nct_id>
  </id_info>
  <brief_title>A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers</brief_title>
  <official_title>A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with&#xD;
      advanced, refractory solid and hematologic cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CC-90002-ST-001 is an open-label, Phase 1, dose escalation, first in human (FIH) clinical&#xD;
      study of CC-90002, administered by intravenous (IV) infusion, in subjects with advanced,&#xD;
      refractory solid and hematologic cancers.&#xD;
&#xD;
      The study will be conducted in two parts. Part A dose escalation phase will explore&#xD;
      escalating dose cohorts of the study drug CC-90002.&#xD;
&#xD;
      Part B dose escalation will explore escalating doses of CC-90002 in combination with&#xD;
      rituximab in subjects with CD20-positive NHL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2015</start_date>
  <completion_date type="Actual">December 24, 2020</completion_date>
  <primary_completion_date type="Actual">December 24, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Number of participants with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-Tolerated Dose (NTD) - Part A</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Dose at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) - Part A</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Dose that is the last dose level below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during Cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-Tolerated Dose (NTD) - Part B</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Dose at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) - Part B</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Dose that is the last dose level below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during Cycle 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor efficacy</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Determined by response rates of each tumor type using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and other tumor-appropriate response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Cycle 1 and beyond; and after discontinuation</time_frame>
    <description>Maximum observed concentration in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC</measure>
    <time_frame>Cycle 1 and beyond; and after discontinuation</time_frame>
    <description>Area under the serum concentration - time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - tmax</measure>
    <time_frame>Cycle 1 and beyond; and after discontinuation</time_frame>
    <description>Time to peak (maximum) serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - T1/2</measure>
    <time_frame>Cycle 1 and beyond; and after discontinuation</time_frame>
    <description>Terminal half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL</measure>
    <time_frame>Cycle 1 and beyond; and after discontinuation</time_frame>
    <description>Total body clearance of the drug from serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vmax</measure>
    <time_frame>Cycle 1 and beyond; and after discontinuation</time_frame>
    <description>Volume of distribution at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies (ADAs)</measure>
    <time_frame>Cycle 1 and beyond; and after discontinuation</time_frame>
    <description>Determine the presence and frequency of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival - Part B</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measured as the time from the first dose of CC-90002 to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival- Part B</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from the first dose of CC-90002 to the first occurrence of disease progression or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part A: CC-90002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: CC-90002 with Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-90002</intervention_name>
    <arm_group_label>Part A: CC-90002</arm_group_label>
    <arm_group_label>Part B: CC-90002 with Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Part B: CC-90002 with Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, 18 years or older, with advanced, relapsed or refractory solid tumors,&#xD;
             Multiple Myeloma (MM) or non-Hodgkin's lymphoma (NHL) in Part A. In Part B, relapsed&#xD;
             and/or refractory CD20-positive NHL subjects only.&#xD;
&#xD;
          2. At least one site of measurable disease in subjects with solid tumors and NHL.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.&#xD;
&#xD;
          4. Subjects must have adequate hematopoietic, liver, renal and coagulation function as&#xD;
             assessed by specific laboratory criteria.&#xD;
&#xD;
          5. Females and males must agree to contraceptive methods and avoid conceiving throughout&#xD;
             the study, and for up to 8 weeks following the last dose of CC-90002. If participating&#xD;
             in Part B, females of child bearing potential should continue to use effective&#xD;
             contraceptive methods for 12 months following treatment with rituximab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. High grade lymphomas (Burkitts or lymphoblastic), plasma cell leukemia.&#xD;
&#xD;
          2. High grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell&#xD;
             tumors, neuroblastoma) with extensive tumor burden.&#xD;
&#xD;
          3. Symptomatic central nervous system involvement.&#xD;
&#xD;
          4. Impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
          5. Prior Red blood cell (RBC) transfusion &lt; 3 months prior to starting CC-90002 (Part A&#xD;
             only).&#xD;
&#xD;
          6. Prior autologous stem cell transplant ≤ 3 months prior to starting CC-90002.&#xD;
&#xD;
          7. Prior allogeneic stem cell transplant with either standard or reduced intensity&#xD;
             conditioning ≤ 6 months prior to starting CC-90002.&#xD;
&#xD;
          8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives&#xD;
             or 4 weeks prior to starting CC-90002, whichever is shorter.&#xD;
&#xD;
          9. Major surgery ≤ 2 weeks prior to starting CC-90002.&#xD;
&#xD;
         10. Pregnant or nursing females.&#xD;
&#xD;
         11. Known HIV infection.&#xD;
&#xD;
         12. Known chronic, active hepatitis B or C (HBV/HCV) infection.&#xD;
&#xD;
         13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.&#xD;
&#xD;
         14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.&#xD;
&#xD;
         15. History of concurrent second cancers requiring active, ongoing systemic treatment.&#xD;
&#xD;
        concurrent second cancers requiring active, ongoing systemic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Burgess, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol Can Ruti</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Val d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duran i Reynals Institut Catala d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-90002</keyword>
  <keyword>Monoclonal</keyword>
  <keyword>Antibody</keyword>
  <keyword>CD47</keyword>
  <keyword>Advanced</keyword>
  <keyword>Solid Cancers</keyword>
  <keyword>Hematologic Cancers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

